Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
about
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity scoreAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.Cure of multiple myeloma -- more hype, less reality.Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Melphalan: old and new uses of a still master drug for multiple myeloma.Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection:The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Kidney disease associated with plasma cell dyscrasiasGuidelines for the diagnosis and management of multiple myeloma 2011.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Guidelines on the diagnosis and management of multiple myeloma 2005.
P2860
Q33376918-33B76131-19FF-46EE-8157-54E74E9A6013Q33558161-8C9F2547-0005-47D3-BEB4-13A866EB4BEFQ33831680-6123C48B-F0C5-4916-A647-9DB0C402248AQ33956039-D74D71A0-80E3-4036-8A72-63406A778F06Q35603608-1747BDE1-2067-412D-9F46-61B9521F7DDBQ35664302-5B2C3D46-A51F-4350-B82A-EF13D84DA857Q35893993-3D04CE2A-DCCE-42ED-8896-44A451BC13BEQ36301128-3507F12A-8744-43EF-AE80-7A77BDA36437Q36373735-98BB2799-5039-4222-A13A-DF75E8551AC8Q36407446-21C0AF92-1964-4190-9CC5-ACEF1FF32FD6Q36902837-0766AC70-1879-461E-A3A1-DB23DAD033A9Q36916889-A5F70675-99C0-4835-93DB-D5C742F73512Q37195567-B232F881-1F5D-412A-85C0-364D586DF5C7Q37209935-FC563854-26F0-4358-BC89-8EA205D8CA96Q37750106-E241686E-7775-41FC-9908-1F1D10D043B9Q37875193-02FE254F-F2BE-4117-83EE-4BDA95D060C3Q37986358-4EFF3296-2C68-46DA-9B0C-498AB516181CQ38109235-02E871C0-3E48-4458-8F4D-C5BAF8059AC4Q38843140-54AD5066-AB36-4AE6-9C93-F8719B69C8C9Q38900024-D5791EF8-EE96-4C46-9929-9755DE4FA33AQ38959138-4F582FED-7584-41FA-A601-3B9B6EC8767DQ39763521-A0566EF1-A7CC-4190-9F52-33BE6EFD1E68Q41714892-5A42E8A3-9758-45F6-8AC6-99ACC25E3491Q45067612-3B7962A7-B9BB-431A-BF4A-615A5FD9FE11Q46804697-F1A579C5-1464-4ED9-A895-37FA6D0ECC8FQ47602198-B069B533-4270-4BEA-A156-9AF247D3B553Q47967442-28825EE4-5C4B-4924-86DC-B8AB601285DAQ48348503-1D167EC2-53CB-42B8-B0B6-17A397249DEEQ53556535-A499B297-411D-4753-AE54-58FF61F51675
P2860
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Autologous stem cell transplan ...... n patients with renal failure.
@en
Autologous stem cell transplan ...... n patients with renal failure.
@nl
type
label
Autologous stem cell transplan ...... n patients with renal failure.
@en
Autologous stem cell transplan ...... n patients with renal failure.
@nl
prefLabel
Autologous stem cell transplan ...... n patients with renal failure.
@en
Autologous stem cell transplan ...... n patients with renal failure.
@nl
P2093
P2860
P1476
Autologous stem cell transplan ...... n patients with renal failure.
@en
P2093
Bendt Nielsen
Christian Geisler
Lene M Knudsen
Peter Gimsing
P2860
P356
10.1111/J.1600-0609.2005.00446.X
P577
2005-07-01T00:00:00Z